Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
Cancer Immunol Res
; 4(4): 289-93, 2016 Apr.
Article
em En
| MEDLINE
| ID: mdl-26865455
ABSTRACT
The recent approval of two PD-1 inhibitors for the treatment of non-small cell lung cancer (NSCLC) has rapidly led to the widespread use of these agents in oncology practices. Pneumonitis has been recognized as a potentially life-threatening adverse event among NSCLC patients treated with PD-1 inhibitors; however, the detailed clinical and radiographic manifestations of this entity remain to be described. We report on two cases of anti-PD-1 pneumonitis in advanced NSCLC patients treated with nivolumab after its FDA approval. Both patients presented with ground-glass and reticular opacities and consolidations in a peripheral distribution on CT, demonstrating a radiographic pattern of cryptogenic organizing pneumonia. Consolidations were extensive and rapidly developed within 8 weeks of therapy in both cases. Both patients were treated with corticosteroids with subsequent improvement of respiratory symptoms and radiographic findings. One patient experienced recurrent pneumonitis after completing corticosteroid taper, or a "pneumonitis flare," in the absence of nivolumab retreatment, with subsequent improvement upon corticosteroid readministration. With the increasing use of immune checkpoint inhibitors in a growing number of tumor types, awareness of the radiographic and clinical manifestations of PD-1 inhibitor-related pneumonitis will be critical for the prompt diagnosis and management of this potentially serious adverse event.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pneumonia
/
Carcinoma Pulmonar de Células não Pequenas
/
Receptor de Morte Celular Programada 1
/
Neoplasias Pulmonares
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Cancer Immunol Res
Ano de publicação:
2016
Tipo de documento:
Article